(1S,2S)-2-[6-(4-fluoro-phenyl)-pyridin-3-yl]-cyclopropanecarboxylic acid ethyl ester | 1037830-76-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (1S,2S)-2-[6-(4-fluoro-phenyl)-pyridin-3-yl]-cyclopropanecarboxylic acid ethyl ester
• 英文别名: ethyl (1S,2S)-2-[6-(4-fluorophenyl)pyridin-3-yl]cyclopropane-1-carboxylate
• CAS: 1037830-76-4
• 化学式: C₁₇H₁₆FNO₂
• 分子量: 285.318
• InChiKey: PKUUVLLKWIIANH-CABCVRRESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  trans-2-[6-(4-fluoro-phenyl)-pyridin-3-yl]-cyclopropanecarboxylic acid ethyl ester 以 乙腈 为溶剂， 生成 (1S,2S)-2-[6-(4-fluoro-phenyl)-pyridin-3-yl]-cyclopropanecarboxylic acid ethyl ester 、 (1 R,2R)-2-[6-(4-fluoro-phenyl)-pyridin-3-yl]-cyclopropanecarboxylic acid ethyl ester
  参考文献：
  名称：

  Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals

  摘要：

  本发明涉及公式I的杂环环丙基羧酰胺，其中Het、X、Ra、Rb、Rc、Rd、R1、R2和R3具有索引中所示的含义，这些化合物调节内皮型一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体来说，公式I的化合物上调内皮型NO合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或恢复降低的NO水平的情况。本发明还涉及制备公式I化合物的方法，包括它们的制剂组合物，以及利用公式I化合物制备用于刺激内皮型NO合酶表达或治疗各种疾病的药物，包括动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏功能不全等心血管疾病。

  公开号：

  EP1942104A1

文献信息

• HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS
  申请人：STROBEL Hartmut

  公开号：US20100016278A1

  公开（公告）日：2010-01-21

  The present invention relates to heteroarylcyclopropanecarboxamides of the formula I, in which Het, X, R a , R b , R c , R d , R 1 , R 2 and R 3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及公式I的杂环芳基环丙烷羧酰胺，其中Het，X，Ra，Rb，Rc，Rd，R1，R2和R3具有声明中所示的含义，这些化合物能够调节内皮型一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体而言，公式I的化合物上调内皮型NO合酶的表达，可应用于需要增加该酶的表达或增加NO水平或正常化降低的NO水平的情况中。本发明还涉及制备公式I化合物的方法，包括它们的制药组合物，并且涉及使用公式I化合物制造用于刺激内皮型NO合酶表达或用于治疗各种疾病的药物，包括心血管疾病，如动脉粥样硬化，血栓形成，冠状动脉疾病，高血压和心脏衰竭等。
• US8299102B2
  申请人：——

  公开号：US8299102B2

  公开（公告）日：2012-10-30
• [EN] HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] HÉTÉROARYL CYCLOPROPANE CARBOXAMIDES ET LEURS UTILISATIONS EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：SANOFI AVENTIS

  公开号：WO2008080511A1

  公开（公告）日：2008-07-10

  [EN] The present invention relates to heteroarylcyclopropanecarboxamides of the formula (I), in which Het, X, R^a, R^b, R^c, R^d, R¹, R² and R³ have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula (I) upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula (I), to pharmaceutical compositions comprising them, and to the use of compounds of the formula (I) for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.
  [FR] La présente invention concerne des hétéroaryl cyclopropane carboxamides de formule (I), dans laquelle Het, X, R^a, R^b, R^c, R^d, R¹, R² et R³ ont les sens indiqués dans les revendications, qui modulent la transcription de l'oxyde nitrique (NO) synthase endothéliale et qui sont de précieux composés pharmacologiquement actifs. Spécifiquement, les composés de formule (I) régulent positivement l'expression de l'enzyme NO-synthase endothéliale et ils peuvent être appliqués dans des conditions dans lesquelles on recherche l'augmentation de l'expression de ladite enzyme, l'augmentation du taux de NO ou la normalisation d'un taux de NO diminué. L'invention concerne en outre des procédés de préparation des composés de formule (I), des compositions pharmaceutiques qui les comprennent et l'utilisation des composés de formule (I) pour la fabrication d'un médicament destiné à la stimulation de l'expression de la NO-synthase endothéliale ou au traitement de diverses maladies, y compris des affections cardiovasculaires telles que l'athérosclérose, la thrombose, la coronaropathie, l'hypertension et l'insuffisance cardiaque, par exemple.